Because of this, TNBC and HER2+ patients are most suitable for immunotherapy, which is an important emerging treatment approach in BC (Figure 2), and most of the BC immunotherapy efforts have focused on these subtypes [29,52]. Here, ERBB2 is linked to breast cancer.